Mantle cell lymphoma
Therapeutic area
Hematology
Rare disease
Yes
- Definition
- Mantle cell lymphoma is a rare form of malignant non-Hodgkin lymphoma affecting B lymphocytes in the lymph nodes in a region called the ``mantle zone''.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Mantle cell lymphoma
- Therapeutic area
- Hematology
- mantle cell lymphoma
- LCM
- MCL
- classical mantle cell lymphoma
- mantle cell lymphoma
- mantle zone lymphoma
- lymphoma, mantle cell
- Severity
- Severe
- Hematology
- Immunology
- Oncology
- MONDO ID
- MONDO:0018876
- Parent condition
- MONDO:0017595
Related records
Broader conditions (19)
- Aggressive B-cell non-Hodgkin lymphoma
- B-cell neoplasm
- B-cell non-Hodgkin lymphoma
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
- Immune system disorder
- Leukocyte disorder
- Lymphoid hemopathy
- Lymphoid neoplasm
- Lymphoma
- Neoplasm
- Neoplastic disease or syndrome
- Non-Hodgkin lymphoma
Narrower conditions (2)
- Gastric mantle cell lymphoma
- Splenic mantle cell lymphoma
Trials (1,221)
- "Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity.
- 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
- 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
- 131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma
- 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
- 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
- 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
- 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
- 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
- A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
- A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
- A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
- A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
- A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
- A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
Approved drugs (10)
- Acalabrutinib
- Acalabrutinib maleate
- Bortezomib D-mannitol
- Brexucabtagene autoleucel
- Ibrutinib
- Lenalidomide
- Lenalidomide hydrochloride monohydrate
- Pirtobrutinib
- Temsirolimus
- Zanubrutinib
Drugs in development (132)
- Abemaciclib Phase 2
- Agatolimod sodium Phase 2
- Alisertib Phase 1
- Alvocidib hydrochloride Phase 1
- AMG-319 Phase 1
- Antineoplaston A10 Phase 2
- Apolizumab Phase 1
- AT-7519 Phase 2
- Axicabtagene ciloleucel Phase 2
- Belinostat Phase 2
- Bendamustine Phase 3
- Bendamustine hydrochloride Phase 2
- Bevacizumab Phase 2
- BMS-387032 Phase 1
- Bryostatin 1 Phase 1
- Buparlisib Phase 2
- Busulfan Phase 2
- Carboplatin Phase 1
- Carfilzomib Phase 2
- Carmustine Phase 3
Other linked drugs (3)
- Bortezomib
- Curcumin
- Orvacabtagene autoleucel